Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...

A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...

Poseida Therapeutics (PSTX) announced the upcoming presentation of new preclinical data supporting the potential of P-KLKB1-101, a ...

A single treatment with, a CRISPR-Cas9-based gene editing therapy, is enough to replace the daily medication of patients with ...

For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regul ...

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...

Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing ...

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with ...

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing ...

Navenibart is an investigational monoclonal antibody that blocks plasma kallikrein. The Food and Drug Administration (FDA) has granted Orphan Drug designation to navenibart for the treatment of ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that five abstracts have been accepted for e-Poster ...

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...